# Valneva SE (VALN) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $5.51, market value $522 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Valneva SE reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 3.3×**. Each dollar of revenue is priced at 3.3×.
- **Price / book: 5.7×**. The shares trade at 5.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -12.4%** (5-yr avg -10.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 16.4%**. Valneva SE keeps 16.4% of revenue after the direct cost of what it sells, a thin margin typical of retail, distribution and commodity businesses.
- **Operating margin: -80.4%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -66.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: -108.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -72.8%**. Return on all capital, debt included, is -72.8%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -39.5%**. Each dollar of assets produces -39.5% of profit.

## Growth
- **Revenue growth (1 yr): 3.0%** (3-yr -21.5%/yr, 5-yr 9.6%/yr). Revenue grew 3.0% over the last year, against 9.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -750.0%**. Earnings per share fell 750.0%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 1.52**. Debt is 1.52 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: net cash**. Valneva SE holds more cash than debt.
- **Interest coverage: -2.8×**. Operating profit covers interest only -2.8×: fragile.
- **Current ratio: 2.38** (quick 2.38). Current assets cover the next year's liabilities 2.38 times.
- **Altman Z-score: 1.59**. A Z-score of 1.59 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Valneva SE does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -42.6%** (YTD -39.7%, 3-mo 4.9%). The shares are down 42.6% over twelve months including dividends.
- **From 52-week high: -54.8%** (16.0% above the low). Trading 55% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 40**. An RSI of 40 is neutral.
- **Beta (1 yr): 0.67** (volatility 66%). Beta of 0.67 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=VALN · Page: https://foliofundamentals.com/stocks/valn

Not investment advice.